ARVN:NSD-Arvinas Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 37.18

Change

+0.17 (+0.46)%

Market Cap

USD 1.97B

Volume

0.35M

Avg Analyst Target

USD 82.00 (+120.55%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ARVN Stock Forecast & Price:
Based on the Arvinas Inc stock forecasts from 14 analysts, the average analyst target price for Arvinas Inc is USD 82.00 over the next 12 months. Arvinas Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Arvinas Inc is Slightly Bullish , which is based on 6 positive signals and 5 negative signals. At the last closing, Arvinas Inc’s stock price was USD 37.18. Arvinas Inc’s stock price has changed by -6.47% over the past week, -16.49% over the past month and -49.70% over the last year.

About Arvinas Inc (ARVN:NSD)

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-12-08 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+1.15 (+0.15%)

USD81.40B 15.14 12.35
VRTX Vertex Pharmaceuticals Inc

+3.74 (+1.18%)

USD80.04B 24.25 17.39
MRNA Moderna Inc

+5.70 (+3.18%)

USD67.59B 6.10 4.60
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+9.18 (+5.64%)

USD39.94B 3.92 1.87
GMAB Genmab AS

+0.12 (+0.26%)

USD29.93B 36.52 3.71
ALNY Alnylam Pharmaceuticals Inc

+6.68 (+2.89%)

USD28.46B N/A -29.83
SGEN Seagen Inc

+5.88 (+4.93%)

USD22.16B 55.02 -38.32
ARGX argenx NV ADR

+5.15 (+1.34%)

USD21.93B N/A -22.20
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ARVN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -54.74% 53% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -54.74% 53% F 31% F
Trailing 12 Months  
Capital Gain -48.46% 62% D- 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.46% 62% D- 35% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 51.76% 89% B+ 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 51.76% 89% B+ 92% A-
Risk Return Profile  
Volatility (Standard Deviation) 90.60% 21% F 13% F
Risk Adjusted Return 57.13% 96% A 89% B+
Market Capitalization 1.97B 92% A- 83% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.90 72% C- 93% A
Price/Book Ratio 3.54 31% F 25% F
Price / Cash Flow Ratio 3.52 7% F 35% F
EV/EBITDA -3.95 76% C 73% C
Management Effectiveness  
Return on Equity -35.10% 74% C 36% F
Return on Invested Capital -27.39% 74% C 32% F
Return on Assets -10.62% 88% B+ 35% F
Debt to Equity Ratio 0.13% 89% B+ 87% B+
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 12.67 12% F 7% F
Short Percent 12.03% 13% F 12% F
Beta 1.80 17% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector